Skip to content

Irish-developed test more accurately predicts risk of distant metastasis in early-stage breast cancer patients

Breast cancer is the most common type of cancer globally, with over 2.3 million occurrences every year. Up to one-in-eight women in Ireland will develop breast cancer in their lifetime, with over 3,700 diagnoses per year. Recurrence after surgical resection is an ongoing challenge in the management of early-stage breast cancer, particularly in cases where…

Read More

Is antibiotic use linked to increased colorectal cancer risk?

Antibiotic usage may be contributing to the increase in early-onset colorectal cancer (CRC) cases observed in recent years, suggests a study presented at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2021. Study author Sarah Perrott, a medical student at the University of Aberdeen in Scotland, noted that rates of early-onset…

Read More

Advances in kidney cancer treatment

The Gathering Around Cancer 2021 conference also heard from Prof Ray McDermott, Consultant Medical Oncologist, St Vincent’s University Hospital, who presented a ‘Renal cancer update’ and provided an overview in the evolution of kidney cancer treatment over the years in Ireland and beyond. “The biggest issue today is choosing which doublet to use in treatment,”…

Read More

Forward momentum in melanoma

The Gathering Around Cancer 2021 conference heard from Dr Derek Power, Consultant Medical Oncologist, Cork University Hospital (CUH), who provided an ‘Update on systemic therapy in melanoma’. Dr Power described how this treatment has “changed dramatically over the past decade… now we have so many drugs, when for many years there was nothing that was…

Read More

Getting it right with Her2+ breast cancer

Gathering Around Cancer 2021, virtual, 4-5 November – Confrenece coverage The Gathering Around Cancer 2021 conference showcased a wide range of national and international speakers who addressed a variety of topics, from cancer treatment, to oncology services, to palliative care, among others. The event was chaired by Prof John McCaffrey, Consultant Medical Oncologist, Mater Misericordiae…

Read More

ASCO 2021 round-up

Priscilla Lynch presents a round-up of some of the most topical research presented at this year’s ASCO Annual Meeting ASCO rapid guideline update for HER2-negative breast cancer Anew American Society of Clinical Oncology (ASCO) guideline update recommends offering one year of adjuvant olaparib to patients with high-risk early-stage human epidermal growth factor receptor 2 (HER2)-negative…

Read More

Addition of immunotherapy to standard of care first-line regimen delays disease progression in advanced NPC

Priscilla Lynch presents a round-up of some of the most topical research presented at this year’s ASCO Annual Meeting The addition of the immunotherapy agent toripalimab to standard first-line chemotherapy significantly delayed disease progression for patients with recurrent or metastatic nasopharyngeal carcinoma (NPC), according to the findings of a phase 3 international study, presented at…

Read More

Both single and dual immunotherapy regimens offer improved overall survival for select patients with advanced oesophageal cancer

Priscilla Lynch presents a round-up of some of the most topical research presented at this year’s ASCO Annual Meeting Compared to standard of care chemotherapy, both a dual immunotherapy regimen and a single immunotherapy agent added to chemotherapy extends overall survival (OS) for patients with advanced oesophageal squamous cell carcinoma, particularly those positive for the…

Read More

Post-surgery immunotherapy extends disease-free survival for select patients with kidney cancer

Priscilla Lynch presents a round-up of some of the most topical research presented at this year’s ASCO Annual Meeting Immunotherapy after surgery significantly improved disease-free survival (DFS) for patients with the most common type of kidney cancer, clear-cell renal carcinoma (RCC). A phase 3 international study, presented at the 2021 ASCO Annual Meeting, found that…

Read More

Immunotherapy delays disease recurrence in patients with early-stage lung cancer

Priscilla Lynch presents a round-up of some of the most topical research presented at this year’s ASCO Annual Meeting Treatment with the immunotherapy checkpoint inhibitor atezolizumab extended disease-free survival (DFS) in patients with resected, early-stage non-small cell lung cancer (NSCLC), particularly those positive for the immune checkpoint protein PD-L1, according to new research presented at…

Read More
Scroll To Top